InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Altman Peter | Director & President and CEO | Purchase | 5,000 | $1.11 | $6K | 280.8K | View ↗ | |
| 2026-04-21 | Altman Peter | Director & President and CEO | Purchase | 400 | $1.23 | $492.00 | 275.8K | View ↗ | |
| 2026-04-20 | Altman Peter | Director & President and CEO | Purchase | 600 | $1.23 | $738.00 | 275.4K | View ↗ | |
| 2026-03-25 | Altman Peter | Director & President and CEO | Purchase | 300 | $1.22 | $366.00 | 274.8K | View ↗ | |
| 2026-03-24 | Altman Peter | Director & President and CEO | Purchase | 600 | $1.24 | $744.00 | 274.5K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Collaboration agreement revenue | $0-100.0% | $58K-87.8% | $477K | — |
| Research and development | $5.0M+13.1% | $4.4M-43.2% | $7.7M-12.5% | $8.8M |
| Selling, general and administrative | $3.3M-9.7% | $3.7M-16.5% | $4.4M-0.5% | $4.4M |
| Total costs and expenses | $8.3M+2.7% | $8.1M-33.5% | $12.1M-8.5% | $13.3M |
| Operating loss | -$8.3M-3.5% | -$8.0M+31.3% | -$11.6M+2.2% | -$11.9M |
| Total other income, net | $50K-9.1% | $55K | — | — |
| Net loss | -$8.2M-3.5% | -$7.9M+31.3% | -$11.6M+2.8% | -$11.9M |
| Net loss per share, basic and diluted (in dollars per share) | -$1K+57.6% | -$3K+64.6% | -$8K-1122.4% | -$670 |
| Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | $6.67B+143.0% | $2.74B+94.3% | $1.41B-92.0% | $17.72B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure
BioCardia, Inc. Q4 2025 Earnings Call Summary
BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ...
BioCardia, Inc. 2025 Q4 - Results - Earnings Call Presentation
BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
BioCardia GAAP EPS of -$1.23 misses by $0.03
BioCardia Reports 2025 Business Highlights and Financial Results
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA